LEO 158968 / LEO Pharma, Novartis - LARVOL DELTA

LEO 158968, a Novel Anti-IL-1RAcP Monoclonal Antibody, Demonstrates a Clear Pharmacokinetic/Pharmacodynamic Relationship and Strong Pharmacological Activity in Patients with Acute Gout: Results from a Phase 1 Program (ACR Convergence 2026) - No abstract available

Clinical • P1 data • PK/PD data • Gout • Inflammatory Arthritis • Rheumatology • IL1RAP

LEO 158968, a Novel Anti-IL-1RAcP Monoclonal Antibody, Demonstrates a Clear PK/PD Relationship and Strong Pharmacological Activity in Patients: Results from a Phase 1 Program (EADV 2026) - No abstract available

Clinical • P1 data • PK/PD data • IL1RAP

Adaptive laboratory evolution of Lactiplantibacillus plantarum enhances furan tolerance and lactic acid production in lignocellulosic hydrolysate. (PubMed, Bioresour Bioprocess) - "Whole-genome resequencing revealed multiple mutations including high-impact non-conservative mutations in genes encoding DNA recombination and repair protein (RecF, lp_0005), flavin prenyltransferase (UbiX lp_0271), and oligo-1,6-glucosidase (lp_0189)...Finally, the adapted strains exhibited improved growth in rice straw hydrolysate and produced significantly higher relative lactic acid yields compared to the parental strain, thus demonstrating improved bioproduction under inhibitor-rich conditions. This study not only provides a comprehensive understanding of L. plantarum's response to lignocellulosic inhibitors, but also yields evolved bacterial candidates for further scientific and industrial exploration."

Journal

LP0189-2318: A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: LEO Pharma | Active, not recruiting ➔ Completed

Trial completion • Gout • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

LP0189-2318: A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: LEO Pharma | Recruiting ➔ Active, not recruiting | N=15 ➔ 6

Enrollment change • Enrollment closed • Gout • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

LP0189-2318: A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: LEO Pharma | Trial completion date: Feb 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Gout • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

LP0189-2318: A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: LEO Pharma | Not yet recruiting ➔ Recruiting

Enrollment open • Gout • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

Investigating the Safety of LEO 158968 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=120 | Completed | Sponsor: LEO Pharma | Active, not recruiting ➔ Completed

Trial completion

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: LEO Pharma

New P1 trial • Gout • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

Investigating the Safety of LEO 158968 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=120 | Active, not recruiting | Sponsor: LEO Pharma | Suspended ➔ Active, not recruiting

Enrollment closed